Anderson, P.L., D.V. Glidden, A. Liu, S. Buchbinder, J.R. Lama, J.V. Guanira, et al. 2012. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science Translational Medicine 4 (151): 151ra125.
Arrivé, E., M.-L. Newell, D.K. Ekouevi, M.-L. Chaix, R. Thiebaut, B. Masquelier, et al. 2007. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis†. International Journal of Epidemiology 36 (5): 1009–1021.
Arts, E.J., and D.J. Hazuda. 2012. HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspectives in Medicine 2 (4): a007161. https://doi.org/10.1101/cshperspect.a007161.
AVAC. PrEP Watch. Scaling up country updates. http://www.prepwatch.org/scaling-up/country-updates
Bavinton, B.R., A.N. Pinto, N. Phanuphak, et al. 2018. Viral suppression and HIV transmission in serodiscordant male couples: An international, prospective, observational, cohort study. Lancet. Published online July 16.
Beckerman, K.P. 2002. Mothers, orphans, and prevention of paediatric AIDS. The Lancet 359 (9313): 1168–1169.
———. 2003. Long-term findings of HIVNET 012: The next steps. The Lancet 362 (9387): 842–843.
Beckham, S.W., C. Beyrer, P. Luckow, M. Doherty, E.K. Negussie, and S.D. Baral. 2016. Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: A systematic review and meta-analysis. Journal of the International AIDS Society 19 (1): 21106.
Bertagnolio, S., I. Derdelinckx, M. Parker, J. Fitzgibbon, H. Fleury, M. Peeters, et al. 2008. World Health Organization/HIVResNet drug resistance laboratory strategy. Antiviral Therapy 13 (Suppl 2): 49–57.
Cambiano, V., S. Bertagnolio, M.R. Jordan, J.D. Lundgren, and A. Phillips. 2013. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. The Journal of Infectious Diseases 207 (Suppl 2): S57–S62.
Chawana, R., and D.K. van Bogaert. 2011. Risk management in HIV/AIDS: Ethical and economic issues associated with restricting HAART access only to adherent patients. African Journal of AIDS Research 10 (sup1): 369–380.
Cohen, Jon. 2004. Allegations raise fears of backlash against AIDS prevention strategy. Science 306 (5705): 2168–2169. https://doi.org/10.1126/science.306.5705.2168.
Cohen, M.S., Y.Q. Chen, M. McCauley, T. Gamble, M.C. Hosseinipour, N. Kumarasamy, et al. 2011. Prevention of HIV-1 infection with early antiretroviral therapy. The New England Journal of Medicine 365 (6): 493–505.
Connor, E.M., R.S. Sperling, R. Gelber, P. Kiselev, G. Scott, M.J. O’Sullivan, et al. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with Zidovudine treatment. The New England Journal of Medicine 331 (18): 1173–1180.
DART Trial Team. 2010. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): A randomised non-inferiority trial. The Lancet 375 (9709): 123–131. https://doi.org/10.1016/S0140-6736(09)62067-5.
Eyakuze, C., D.A. Jones, A.M. Starrs, and N. Sorkin. 2008. From PMTCT to a more comprehensive aids response for women: A much-needed shift. Developing World Bioethics 8 (1): 33–42.
Grant, R.M., P.L. Anderson, V. McMahan, A. Liu, K.R. Amico, M. Mehrotra, et al. 2014. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A cohort study. The Lancet Infectious Diseases 14 (9): 820–829.
Guay, L.A., P. Musoke, T. Fleming, D. Bagenda, M. Allen, C. Nakabiito, et al. 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. The Lancet 354 (9181): 795–802.
Gulick, Roy M., Heather J. Ribaudo, Cecilia M. Shikuma, Stephanie Lustgarten, Kathleen E. Squires, William A. Meyer III, Edward P. Acosta, Bruce R. Schackman, Christopher D. Pilcher, Robert L. Murphy, William E. Maher, Mallory D. Witt, Richard C. Reichman, Sally Snyder, Karin L. Klingman, and Daniel R. Kuritzkes. 2004. Triple-Nucleoside regimens versus Efavirenz-containing regimens for the initial treatment of HIV-1 infection. New England Journal of Medicine 350 (18): 1850–1861. https://doi.org/10.1056/NEJMoa031772.
Haire, B. 2015. Preexposure prophylaxis-related stigma: Strategies to improve uptake and adherence – A narrative review. HIV/AIDS – Research and Palliative Care 7: 241–249. https://doi.org/10.2147/HIV.S72419.
Ho, David D. 1995. Time to hit HIV, early and hard. New England Journal of Medicine 333 (7): 450–451. https://doi.org/10.1056/nejm199508173330710.
Institute of Medicine (US) Committee on Reviewing the HIVNET 012 Perinatal HIV Prevention Study. 2005. Review of the HIVNET 012 perinatal HIV prevention study. National Academy of Sciences. Washington, DC: National Academies Press.
Johnson, J.A., Li J-f, L. Morris, N. Martinson, G. Gray, J. McIntyre, et al. 2005. Emergence of drug-resistant HIV-1 after Intrapartum administration of single-dose Nevirapine is substantially underestimated. The Journal of Infectious Diseases 192 (1): 16–23.
Kaufmann, G.R., H. Furrer, B. Ledergerber, L. Perrin, M. Opravil, P. Vernazza, M. Cavassini, E. Bernasconi, M. Rickenbach, B. Hirschel, and M. Battegay. 2005. Characteristics, determinants, and clinical relevance of CD4 T cell recovery <500 Cells/μL in HIV type 1 – Infected individuals receiving potent antiretroviral therapy. Clinical Infectious Diseases 41 (3): 361–372. https://doi.org/10.1086/431484.
Kébé, K., L. Bélec, H.D. Ndiaye, S.B. Gueye, A.A.M. Diouara, S. Ngom, et al. 2014. The case for addressing primary resistance mutations to non-nucleoside reverse transcriptase inhibitors to treat children born from mothers living with HIV in sub-Saharan Africa. Journal of the International AIDS Society 17 (1): 18526.
Knox, D.C., D.H. Tan, P.R. Harrigan, and P.L. Anderson. 2016. HIV-1 infection with multiclass resistance despite Preexposure Prophylaxis (PrEP). 169aLB. In Conference on retro viruses and opportunistic infections, 22–25 February 2016, Boston, Massachusetts.
Lockman, S., R.L. Shapiro, L.M. Smeaton, C. Wester, I. Thior, L. Stevens, F. Chand, J. Makhema, C. Moffat, A. Asmelash, P. Ndase, P. Arimi, E. van Widenfelt, L. Mazhani, V. Novitsky, S. Lagakos, and M. Essex. 2007. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. New England Journal of Medicine 356 (2): 135–147. https://doi.org/10.1056/NEJMoa062876.
Luber, A.D. 2005. Genetic barriers to resistance and impact on clinical response. Medscape General Medicine 7 (3): 69.
Macklin, R. 2001. After Helsinki: Unresolved issues in international research. Kennedy Institute of Ethics Journal 11 (1): 17–36. Project MUSE. https://doi.org/10.1353/ken.2001.0005.
———. 2004. Ethics and equity in access the HIV treatment 3 by 5 initiative: Background paper consultation on ethics and equitable access to treatment and care for HIV/AIDS. http://www.who.int/ethics/background-macklin2.pdf
McConnell, M.S., J.S.A. Stringer, A.P. Kourtis, P.J. Weidle, and S.H. Eshleman. 2007. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: Does development of resistance matter? American Journal of Obstetrics & Gynecology 197 (3): S56–S63.
Mellors, J.W., C.R. Rinaldo, P. Gupta, R.M. White, J.A. Todd, and L.A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (5265): 1167–1170.
Mellors, J.W., A. Munoz, J.V. Giorgi, et al. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 126 (12): 946–954.
Moore, R.D., and R.E. Chaisson. 1999. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 13 (14): 1933–1942.. PMID 10513653. https://doi.org/10.1097/00002030-199910010-00017.
Pharmacychecker. 2017. https://www.pharmacychecker.com/generic/price-comparison/zidovudine/300+mg. Accessed 29 July 2017.
Rodger AJ et al. for the PARTNER Study Group. 2016. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 316 (2): 1–11. https://doi.org/10.1001/jama.2016.5148. http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.5148. Accessed 12 July 2016.
Rodger AJ, V. Cambiano, T. Bruun, et al. 2018. Risk of HIV transmission through condomless sex in MSM couples with suppressive ART: The PARTNER2 Study extended results in gay men. In 22nd International AIDS conference (AIDS 2018), Amsterdam, the Netherlands. Oral Abstract WEAX0104LB.
Rosen, S., and M.P. Fox. 2011. Retention in HIV care between testing and treatment in Sub-Saharan Africa: A systematic review. PLOS Medicine 8 (7): e1001056.
Rowley, C.F., I.J. MacLeod, D. Maruapula, B. Lekoko, S. Gaseitsiwe, M. Mine, et al. 2016. Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance. Journal of Antimicrobial Chemotherapy 71 (5): 1361–1366.
Samuel, R., M.N. Julian, R. Paredes, R. Parboosing, P. Moodley, L. Singh, et al. 2016. HIV-1 drug resistance by ultra-deep sequencing following short course zidovudine, single-dose nevirapine, and single-dose tenofovir with emtricitabine for prevention of mother-to-child transmission. JAIDS Journal of Acquired Immune Deficiency Syndromes 73 (4): 384–389.
Severe, Patrice, Marc Antoine Jean Juste, Alex Ambroise, Ludger Eliacin, Claudel Marchand, Sandra Apollon, Alison Edwards, Heejung Bang, Janet Nicotera, Catherine Godfrey, Roy M. Gulick, Warren D. Johnson Jr., Jean William Pape, and Daniel W. Fitzgerald. 2010. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. New England Journal of Medicine 363 (3): 257–265. https://doi.org/10.1056/NEJMoa0910370.
Smart, T. 2006. PEPFAR and Global Fund both highly effective, but is the funding sustainable? AIDSMAP. http://www.aidsmap.com/PEPFAR-and-Global-Fund-both-highly-effective-but-is-the-funding-sustainable/page/1424121. Accessed 23 June 2006.
Strategies for Management of Antiretroviral Therapy Study Group, Sean Emery, Jacqueline A. Neuhaus, Andrew N. Phillips, Abdel Babiker, Calvin J. Cohen, Jose M. Gatell, Pierre-Marie Girard, Birgit Grund, Matthew Law, Marcelo H. Losso, Adrian Palfreeman, and Robin Wood. 2008. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. The Journal of Infectious Diseases 197 (8): 1133–1144. https://doi.org/10.1086/586713.
Stringer, J.S.A., M.S. McConnell, J. Kiarie, O. Bolu, T. Anekthananon, T. Jariyasethpong, et al. 2010. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: A multi-country, prospective cohort study. PLOS Medicine 7 (2): e1000233.
Taylor-Smith, K., H. Tweya, A. Harries, E. Schoutene, and A. Jahn. 2010. Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Medical Journal: The Journal of Medical Association of Malawi 22 (2): 49–56.
Tenthani, Lyson, Andreas D. Haas, Hannock Tweya, Andreas Jahn, Joep J. van Oosterhout, Frank Chimbwandira, Zengani Chirwa, Wingston Ng’Ambi, Alan Bakali, Sam Phiri, Landon Myer, Fabio Valeri, Marcel Zwahlen, Gilles Wandeler, and Olivia Keiser. 2014. Retention in care under universal antiretroviral therapy for HIV infected pregnant and breastfeeding women (“Option B+”) in Malawi. AIDS 28 (4): 589–598. https://doi.org/10.1097/QAD.0000000000000143.
The INSIGHT START Study Group. 2015. Initiation of antiretroviral therapy in early asymptomatic HIV infection. New England Journal of Medicine 373 (9): 795–807. https://doi.org/10.1056/NEJMoa1506816.
UNAIDS. 2017. 90–90–90 – An ambitious treatment target to help end the aids epidemic. http://www.unaids.org/en/resources/documents/2017/90-90-90
Wade, N.A., G.S. Birkhead, B.L. Warren, T.T. Charbonneau, P.T. French, L. Wang, et al. 1998. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. New England Journal of Medicine 339 (20): 1409–1414.
Wilfert, C.M. 2003. HIVNET 012 and Petra. The Lancet 363 (9404): 244–245.
World Health Organization. 2003a. 3 by 5 Strategy: Making it happen. http://www.who.int/3by5/publications/documents/en/3by5StrategyMakingItHappen.pdf
———. 2003b. Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. http://www.who.int/hiv/pub/prev_care/en/ARTrevision2003en.pdf?ua=1
———. 2006. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach (2006 revision). http://www.who.int/hiv/pub/ART/adult/en
———. 2009. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf
——— 2016. Global Action Plan on HIV Drug Resistance 2017–2021. https://www.who.int/hiv/drugresistance/hivdr_darft_gap.pdf
———. 2017. HIV drug resistance report 2017. Geneva: World Health Organization. http://apps.who.int/iris/bitstream/handle/10665/255896/9789241512831-eng.pdf;jsessionid=9AFD8EB2096DEF42908467A854A90A9E?sequence=1
———. 2018. WHO HIV data and statistics. http://www.who.int/hiv/data/en